GRI Bio Financials
This page shows GRI Bio (GRI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Fresh capital raises rather than operations are carrying this research-stage business, where cash burn tracks spending almost directly.
From FY2023 to FY2025, financing inflows repeatedly exceeded free-cash outflows, which is why cash climbed to$8.229M by FY2025 even though the business still did not fund itself internally. That outside funding also rebuilt shareholders’ equity to$6.008M while liabilities were only$2.658M , making the balance sheet far less thinly capitalized than it was two years earlier.
FY2025 net loss of
R&D spending rose to
Financial Health Signals
GRI Bio does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
GRI Bio passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
GRI Bio reported a net loss of $12.0M while operations used $10.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
GRI Bio's EBITDA was -$12.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 45.5% from the prior year.
GRI Bio reported -$12.0M in net income in fiscal year 2025. This represents a decrease of 45.7% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
GRI Bio recorded an outflow of $10.2M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 18.3% from the prior year.
GRI Bio held $8.2M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
GRI Bio's ROE was -199.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 4.5 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
GRI Bio invested $6.8M in research and development in fiscal year 2025. This represents an increase of 81.0% from the prior year.
GRI Bio invested $3K in capex in fiscal year 2025, funding long-term assets and infrastructure.
Not reported for fiscal year 2025.
GRI Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | $0-100.0% | $100K |
| R&D Expenses | N/A | $6.8M+81.0% | $3.8M+16.6% | $3.2M+1235.5% | $242K-95.3% | $5.2M+39.9% | $3.7M |
| SG&A Expenses | N/A | $5.2M+15.5% | $4.5M-45.2% | $8.2M | N/A | $4.1M+244.8% | $1.2M |
| Operating Income | N/A | -$12.0M-45.4% | -$8.2M+27.7% | -$11.4M | N/A | -$9.3M | N/A |
| Income Tax | N/A | $3K+50.0% | $2K | N/A | N/A | N/A | N/A |
| Net Income | N/A | -$12.0M-45.7% | -$8.2M+37.0% | -$13.0M | N/A | -$9.3M | N/A |
| EPS (Diluted) | — | -$121.80 | -$1545.55 | -$5018.09 | -$24.95 | -$1.42-32.7% | -$1.07 |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
GRI Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| Total Assets | $8.7M+51.0% | $5.7M+94.1% | $3.0M+671.8% | $383K-95.4% | $8.3M+772.8% | $955K |
| Current Assets | $8.6M+53.0% | $5.6M+91.4% | $2.9M+840.4% | $312K-96.2% | $8.1M+1106.1% | $674K |
| Cash & Equivalents | $8.2M+63.7% | $5.0M+178.1% | $1.8M+19988.9% | $9K-99.8% | $3.7M+3296.3% | $109K |
| Total Liabilities | $2.7M+55.7% | $1.7M-36.7% | $2.7M+34.3% | $2.0M-84.8% | $13.2M+447.2% | $2.4M |
| Current Liabilities | $2.6M+61.6% | $1.6M-39.3% | $2.7M+35.3% | $2.0M-18.4% | $2.4M+9.9% | $2.2M |
| Total Equity | $6.0M+49.0% | $4.0M+1456.8% | $259K+115.9% | -$1.6M+66.5% | -$4.8M-233.4% | -$1.5M |
| Retained Earnings | -$51.7M-30.1% | -$39.7M-26.0% | -$31.5M-70.5% | -$18.5M+15.6% | -$21.9M-73.8% | -$12.6M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
GRI Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$10.4M | -$10.2M-18.3% | -$8.6M+4.2% | -$9.0M-728.6% | -$1.1M+86.9% | -$8.3M-124.3% | -$3.7M |
| Capital Expenditures | N/A | $3K | $0-100.0% | $8K+166.7% | $3K | $0-100.0% | $2K |
| Free Cash Flow | N/A | -$10.2M-18.3% | -$8.6M+4.3% | -$9.0M-727.0% | -$1.1M+86.9% | -$8.3M-124.2% | -$3.7M |
| Investing Cash Flow | N/A | -$3K | $0+100.0% | -$8K-166.7% | -$3K+99.9% | -$3.8M-192000.0% | -$2K |
| Financing Cash Flow | $16.2M | $13.4M+13.2% | $11.8M+9.6% | $10.8M+972.2% | $1.0M-93.6% | $15.7M+393775.0% | -$4K |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
GRI Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| Return on Equity | -199.0%+4.5pp | -203.5%+4830.0pp | -5033.6% | N/A | N/A | N/A |
| Return on Assets | -138.0%+5.0pp | -143.0%+298.0pp | -441.0% | N/A | -111.6% | N/A |
| Current Ratio | 3.25-0.2x | 3.43+2.3x | 1.09+0.9x | 0.16-3.2x | 3.32+3.0x | 0.30 |
| Debt-to-Equity | 0.440.0x | 0.42-10.0x | 10.41 | N/A | N/A | N/A |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | -3708.0% |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: FCF Margin.
Similar Companies
Where GRI Bio Ranks
Frequently Asked Questions
Is GRI Bio profitable?
No, GRI Bio (GRI) reported a net income of -$12.0M in fiscal year 2025.
What is GRI Bio's EBITDA?
GRI Bio (GRI) had EBITDA of -$12.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is GRI Bio's return on equity (ROE)?
GRI Bio (GRI) has a return on equity of -199.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is GRI Bio's free cash flow?
GRI Bio (GRI) recorded an outflow of $10.2M in free cash flow during fiscal year 2025. This represents a -18.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is GRI Bio's operating cash flow?
GRI Bio (GRI) recorded an outflow of $10.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are GRI Bio's total assets?
GRI Bio (GRI) had $8.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What are GRI Bio's capital expenditures?
GRI Bio (GRI) invested $3K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does GRI Bio spend on research and development?
GRI Bio (GRI) invested $6.8M in research and development during fiscal year 2025.
What is GRI Bio's current ratio?
GRI Bio (GRI) had a current ratio of 3.25 as of fiscal year 2025, which is generally considered healthy.
What is GRI Bio's debt-to-equity ratio?
GRI Bio (GRI) had a debt-to-equity ratio of 0.44 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is GRI Bio's return on assets (ROA)?
GRI Bio (GRI) had a return on assets of -138.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is GRI Bio's cash runway?
Based on fiscal year 2025 data, GRI Bio (GRI) had $8.2M in cash against an annual operating cash burn of $10.2M. This gives an estimated cash runway of approximately 10 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is GRI Bio's Piotroski F-Score?
GRI Bio (GRI) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are GRI Bio's earnings high quality?
GRI Bio (GRI) reported a net loss of $12.0M while operations used $10.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.